

DAFTAR PUSTAKA

1. Wells G, DiPiro T, Schwinghammer L, DiPiro V. *Pharmacotherapy Handbook*. 10th ed. USA: Mc Graw-Hill Education; 2017.
2. Katzung G, Masters B, Trevor J. *Basic & Clinical Pharmacology*. 12th ed. New York: Mc Graw-Hill Medical; 2012.
3. Direktorat Bina Farmasi Komunitas dan Klinik. *Pharmaceutical Care Untuk Penyakit Hipertensi*. Departemen Kesehatan Ditjen Bina Kefarmasian; 2006.
4. International Diabetes Federation. *IDF Diabetes Atlas*, 10th edition [Internet]. 2021 [cited 2024 Sep 3]. Available from: <https://www.diabetesatlas.org/>
5. Soeatmadji, Rosandi R, Djoko W, et al. Clinicodemographic Profile and Outcomes of Type 2 Diabetes Mellitus in the Indonesian Cohort of Discover: A 3-Year Prospective Cohort Study. *J ASEAN Fed Endocr Soc*. 2023;38(1):68–74.
6. Dinas Kesehatan Sumatera Barat. *Profil Kesehatan Provinsi Sumatera Barat Tahun 2019* [Internet]. 2019 [cited 2024 Sep 3]. Available from: <http://dinkes.sumbarprov.go.id/details/news/450>
7. Saibi Y, Hasan D, Verona S. Potensi Interaksi Obat pada Pasien Diabetes Melitus Tipe 2 di Rumah Sakit X Tangerang Selatan. *JMPF*. 2018;8(3):100–4.
8. Rasdianah N, Madania M, Pakaya M. Studi Interaksi Obat Pasien Diabetes Melitus Tipe 2 Dengan Penyakit Penyerta : Studi Kasus Rumah Sakit X Gorontalo. *Journal Syifa Sciences and Clinical Research*. 2023 Mar 31;5(1).
9. Tanto C, Hustrini M. *Sindrom Nefrotik*. 4th ed. Vol. II. Jakarta: Media Aeculapius; 2014.
10. Sankar V, Saaed Y, Joseph R, Azizi H, Thomas P. Serious Drug-Drug Interactions in the Prescriptions of Diabetic Patients. *Medical Sciences*. 2015 Oct 1;3(4):93–103.
11. Permatasari D, Husna NA, Yosmar R. Potential Drug-Drug Interactions of Cardiovascular Drugs Based on Literature in Geriatric Patients with Congestive Heart Failure at Dr. M. Djamil Padang Hospital. *International Journal of Applied Pharmaceutics*. 2024 Feb 1;16(Special Issue 1):28–34.
12. Yosmar R, Shepany E, Fitria N. A Comprehensive Analylis of Antidiabetic Drug Interactions In Geriatric Noninsulin Dependent Diabetes Mellitus Patients. *International Journal of Applied Pharmaceutics*. 2024 Feb 1;16(Special Issue 1):62–5.

13. Saputri G, Angin M, Ningsih E. Evaluasi Interaksi Obat Pada Pasien Diabetes Melitus Tipe 2 dengan Komplikasi Hipertensi di Rumah Sakit Pertamina Bintang Amin Tahun 2020. *Jurnal Farmasi Himalayati*. 2022;5:250.
14. Afifah H, Rachmawati E, et al. Drug Interaction Study in Type 2 Diabetes Mellitus with Hypertension Patients at X Hospital, Jember Regency. *Jurnal Farmasimed (JFM)*. 2024 Apr 30;6(2):131–41.
15. Dungan K, Merrill J, Long C, Binkley P. Effect of Beta Blocker Use and Type on Hypoglycemia Risk Among Hospitalized Insulin Requiring Patients. *Cardiovasc Diabetol*. 2019 Nov 27;18(1).
16. PERKENI. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2021. Jakarta: Pb.Perkeni; 2021.
17. Betram G, Katzung MD. *Farmakologi Dasar dan Klinik*. 12th ed. New York: The McGraw-Hill Companies; 2012.
18. Akil, Taringan P. *Buku Ajar Ilmu Penyakit Dalam*. Jakarta: Pusat Penerbitan IPD FK UI; 2006.
19. Khan M, Hashim M, King J, et al. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. *J Epidemiol Glob Health*. 2020 Mar 1;10(1):107–11.
20. Perkumpulan Endokrinologi Indonesia. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 DI Indonesia 2021. Jakarta: PB. Perkeni; 2021.
21. Galicia U, Benito A, et al. Pathophysiology of Type 2 Diabetes Mellitus. *Int J Mol Sci*. 2020 Sep 1;21(17):1–34.
22. Pratley RE. The Early Treatment of Type 2 Diabetes. *American Journal of Medicine*. 2013;126(9 SUPPL.1).
23. KEMENKES RI. Standar Pelayanan Kefarmasian Diabetes Melitus. Jakarta: Kementrian Kesehatan RI; 2019.
24. PERKENI. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia-2019. Jakarta: Pb.Perkeni; 2019.
25. Farmaki P, Damaskos C, et al. Complications of the Type 2 Diabetes Mellitus. *Curr Cardiol Rev*. 2020;16(5):249–51.
26. Ichsantiarini A, Nugroho P. Hubungan Diabetes Melitus Tipe 2 dengan Kendali Tekanan Darah Pada Pasien Hipertensi Rumah Sakit DR.Cipto Mangkusumo. FK UI. 2013;

27. Julianti I. Hubungan Antara Kadar Gula Darah dengan Tekanan Darah Pada Pasien Diabetes Melitus Tipe II. Universitas Wijaya Kusuma Surabaya. 2021.
28. Endokrinologi Anak Dan Remaja. Konsensus Nasional Pengelolaan Diabetes Melitus Tipe 2 Pada Anak dan Remaja. Jakarta: Ikatan Dokter Anak dan Remaja; 2015.
29. International Pharmaceutical Federation (FIP). Diabetes FIP Practice Transformation Programme on NCDs Diabetes Prevention, Screening and Management: A Handbook for Pharmacists [Internet]. The Hague: International Pharmaceutical Federation; 2021. Available from: www.fip.org
30. Fatma M, Eros E, Suryati S, Badriah S, Rizqi S, Fahira N, et al. Hipertensi: Kenali Penyebab, Tanda Gejala dan Penanganannya. Jubaedi A, editor. Jakarta: Poltekkes Jakarta; 2021.
31. Kario K, Okura A, Hoshida S, Mogi M. The WHO Global Report 2023 on Hypertension Warning the Emerging Hypertension Burden in Globe and Its Treatment Strategy. *Hypertension Research*. 2024 May 1;47(5):1099–102.
32. World Health Organization (WHO). Indonesia Hypertension Profile. World Health Organization. 2023;
33. Harrison D, Coffman TM, Wilcox C. Pathophysiology of Hypertension: The Mosaic Theory and Beyond. *Circ Res*. 2021 Apr 2;128(7):847–63.
34. PERKI. Pedoman Tatalaksana Hipertensi Pada Penyakit Kardiovaskular. 1st ed. Jakarta: Perhimpunan Dokter Spesialis Kardiovaskular Indonesia; 2015.
35. Kandarini Y. Tatalaksana Farmakologi Terapi Hipertensi. Denpasar; 2017.
36. American College of Cardiology. Guidline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension AHA [Internet]. 2018;71:13–115. Available from: www.acc.org
37. Verma N, Rastogi S, Chia YC, Siddique S, Turana Y, Cheng H min, et al. Non-Pharmacological Management of Hypertension. *J Clin Hypertens*. 2021 Jul 1;23(7):1275–83.
38. Baxter K. Stockley's Drug Interactions. 9th ed. Pharmaceutical Press; 2010.
39. Santos T, Macieira G M, et al. Prevalence of Clinically Manifested Drug Interactions in Hospitalized Patients: A Systematic Review and Meta-Analysis. *PLoS One*. 2020;15(7).
40. Gabay M, Spencer SH. Drug Interactions: Scientific and Clinical Principles. PSAP. 2021;

41. Bushra R, Aslam N, Khan A. Food-Drug Interactions. Oman Medical Specialty Board Oman Medical Journal. 2011;26(2):77–83.
42. Snyder BD, Polasek TM, Doogue MP. Drug Interactions: Principles and Practice. Aust Prescr. 2012;35(3):85–8.
43. David R. Drug-Drug Interactions. 2nd ed. Vol. 179. USA: Informa Healthcare; 2008.
44. Hasnain H, Ali H, Zafar F, Sial AA, Hameed K, Shareef H, et al. Drug-Drug Interaction; Facts and Comparisons with National and International Bench Marks. A Threat More Than a Challenge for Patient Safety In Clinical And Economic Scenario. The Professional Medical Journal. 2017 Mar 1;24(03):357–65.
45. Tatro D. Drug Interaction Facts. California: Wolters Kluwer; 2008.
46. Rakshith UR, Nair SP, Ranganath AH, Halagali P. Drug Interactions: Mechanisms, Assessment and Management Strategies. Journal of Young Pharmacists. 2024 Aug 23;16(3):447–55.
47. Adiputra I, Siregar D, et al. Statistik Kesehatan Teori dan Aplikasi. Denpasar: Yayasan Kita Menulis; 2021.
48. Al-Hadi H, Aandy Saida S. Prevalensi Diabetes Melitus Tipe 2 dengan Kejadian Hipertensi di Poliklinik Penyakit Dalam RS Pertamamedika Ummi Rosnati. Jurnal Medika Malahayati. 2020;4(4).
49. Sabrini AM, Febrianty F, Natasha N, Shafira A. Karakteristik Pasien DM TIPE 2 dengan Hipertensi di Poliklinik Penyakit Dalam RSUD Raden Mattaher Jambi Tahun 2016-2019. JOMS. 2022;2(2).
50. Malaguarnera M, Vacante M, Frazzetto PM, Motta M. The Role of Diabetes and Aging in the Determinism of Hypertension and the Related Cerebrovascular Complications. Arch Gerontol Geriatr. 2012 Sep;55(2):221–5.
51. Nasution YA, Lubis Z, Siregar A. Risk Factors of Type 2 Diabetes Mellitus in Elderly. Journal of Epidemiology and Public Health. 2021;(02):232–44.
52. Naseri MW, Esmat HA, Bahee MD. Prevalence of Hypertension in Type-2 Diabetes Mellitus. Annals of Medicine and Surgery. 2022 Jun 1;78.
53. Gradidge PJJ, Norris SA, Jaff NG, Crowther NJ. Metabolic and Body Composition Risk Factors Associated with Metabolic Syndrome in a Cohort of Women with a High Prevalence of Cardiometabolic Disease. PLoS One. 2016 Sep 1;11(9).
54. Huebschmann AG, Huxley RR, Kohrt WM, Zeitler P, Regensteiner JG, Reusch JEB. Sex Differences in the Burden of Type 2 Diabetes and

Cardiovascular Risk Across the Life Course. Vol. 62, Diabetologia. Springer Verlag; 2019. p. 1761–72.

55. Elsayed, Nuha A, et al. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. *Diabetes Care*. 2025 Jan 1;48(1): S181–206.
56. Eledrisi MS, Danjuma MIM. Comparison of Insulin Analogs and Human Insulins: A Narrative Review. *Journal of Diabetes and Endocrine Practice*. 2024 Jan;07(1):5–14.
57. Raz I. Guideline Approach to Therapy in Patients with Newly Diagnosed Type 2 Diabetes. *Diabetes Care*. 2013 Aug;36(2).
58. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the Management of Arterial Hypertension. *J Hypertens*. 2023 Dec 1;41(12):1874–2071.
59. Rachmawati S, Pratiwi F, Norcahyanti I. Medication Profile and Potential drug Interactions in Diabetes Mellitus with Hypertension Outpatient at RSUD dr. H. Andi Abdurrahman Noor. *Jurnal Ilmiah Farmasi*. 2022 Jan 31;60–7.
60. Thomas A, Anders R, et al. *Drug-Drug Interactions Scientific and Regulatory Perspectives*. New York: Academic Press; 1997.
61. Hidayah K, Kundarto W, Farida Y. Identifikasi Potensi Interaksi Obat pada Peresepan Obat Pasien Hipertensi dengan Diabetes Mellitus. *Annual Pharmacy Conference*. 2017;
62. Natanael J, Damayanti E, Himayani R. Literature Review: Kajian Potensi Interaksi Obat Antidiabetes pada Pasien Diabetes Melitus Tipe 2 dengan Komplikasi Hipertensi. *Sains Medisina*. 2024 Aug;2(6).
63. Roberts AG, Gibbs ME. Mechanisms and the Clinical Relevance of Complex Drug–Drug Interactions. *Clin Pharmacol*. 2018;10:123–34.
64. Drugs.com [Internet]. https://www.drugs.com/drug_interactions.html. 2024. Drug Interaction Checker.
65. Medscape Reference. <https://reference.medscape.com/drug-interactionchecker>. 2023. Drug Interaction Checker.
66. Madania, Rasdianah N, Dalu M, Pakaya M. Potensi Interaksi Obat Pasien Hipertensi dan Diabetes Melitus Tipe 2 di Instalasi Rawat Jalan RSUD Toto Kabila. *Pharmacosript*. 2022;5(1):56–62.
67. Drugbank Online [Internet]. <https://go.drugbank.com/drug-interaction-checker>. 2024. Drug Interaction Checker.

68. Neli, Susilawati Y. Identifikasi Interaksi Obat pada Resep Pasien Gangguan Pencernaan di Apotek X Periode Februari 2023. *Farmaka*. 2023;21(3).
69. Lawere RA, Tiwow GAR, Palandi RR, Saroinsong YF, Mongi J. Evaluasi Interaksi Obat Diabetes Pada Pasien Geriatri Di Instalasi Rawat Inap Rumah Sakit Lapangan Sawang Kabupaten Sitaro Tahun 2016. *Jurnal Biofarmasetikal Tropis*. 2021(2):8–14.
70. Muti A, Yani A, Refdanita R. Studi Potensi Interaksi Obat pada Pasien Fraktur di RSUD Tarakan Jakarta. *PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia)*. 2020 Dec 31;17(2):317.
71. Fitriani A, Padmasari S. Analisis Potensi Interaksi Obat Antidiabetik Pada Pasien Diabetes Melitus Tipe 2 Rawat Inap RS PKU Muhammadiyah Gamping Yogyakarta. *Majalah Farmaseutik*. 2022 Jan 31;18(1):37.
72. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is Polypharmacy? A systematic Review of Definitions. *BMC Geriatr*. 2017 Oct 10;17(1).
73. Salwe KJ, Kalyansundaram D, Bahurupi Y. A Study on Polypharmacy and Potential Drug-Drug Interactions Among Elderly Patients Admitted in Department of Medicine of a Tertiary Care Hospital in Puducherry. *Journal of Clinical and Diagnostic Research*. 2016 Feb 1;10(2):FC06-FC10.
74. Reeve E, Gnjdic D, Long J, Hilmer S. a Systematic Review of the Emerging Definition of ‘Deprescribing’ with Network Analysis: Implications for Future Research and Clinical Practice. *Br J Clin Pharmacol*. 2015 Dec 1;80(6):1254–68.

